ANDA 78883, held by Matrix Labs. Efavirenz.
As of Nov 16, 2026, ANDA 78883 (Efavirenz), held by Matrix Labs, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 25, 2008 | Original application | Tentative approval |
| Product | Active ingredient | Marketing |
|---|---|---|
| Efavirenz600MG ยท tablet; oral | Efavirenz | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters